SCHEMBL18620488

SCHEMBL18620488

COC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(O)c(O)c1

nearest known ligand 0.74

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.64
MEN1 O00255 3/20 0.64
HCRTR1 O43613 1/20 0.64
NPBWR1 P48145 1/20 0.63
MCHR1 Q99705 1/20 0.63
ERAP2 Q6P179 1/20 0.61
LNPEP Q9UIQ6 1/20 0.61
TACR1 P25103 4/20 0.61
MAPT P10636 2/20 0.58
TP53 P04637 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ITGB2 P05107 1/20 0.57
ICAM1 P05362 1/20 0.57
ITGAL P20701 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20356918 1.00 KMT2A (0.64) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL22292158 1.00 KMT2A (0.64) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL9088495 0.86 TACR1 (0.64) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL9088492 0.86 TACR1 (0.64) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL14565643 0.86 KMT2A (0.60) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL1921333 0.85 NPC1 (0.62) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL1921332 0.85 NPC1 (0.62) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL13606614 0.85 NPC1 (0.62) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL15145383 0.84 KMT2A (0.66) KMT2AMEN1HCRTR1NPBWR1MCHR1
SCHEMBL15145386 0.84 KMT2A (0.65) KMT2AMEN1HCRTR1NPBWR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP claimed
CN-108602837-B Compound having platelet aggregation inhibitory effect, salt thereof, and composition for preventing or treating thrombotic diseases comprising same 新丰制药株式会社 2022-02-11 CN claimed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US claimed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US claimed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP claimed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
CN-108602837-B Compound having platelet aggregation inhibitory effect, salt thereof, and composition for preventing or treating thrombotic diseases comprising same 新丰制药株式会社 2022-02-11 CN disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
WO-2017039395-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME 신풍제약 주식회사 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same PLA2G7, JAK2, PF4 KMT2A 3505/4885MEN1 2227/4885HCRTR1 4825/4885
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same PLA2G7, JAK2, PF4 KMT2A 3505/4885MEN1 2227/4885HCRTR1 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.